StoneX Group’s Corbus Pharmaceuticals CRBP Stock Holding History

StoneX Group’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-437	Closed	-$1.45K	–	488
2022 Q4	$1.45K	Buy	+437	New	+$1.68K	﹤0.01%	552

Other funds holding CRBP

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

StoneX Group's CRBP Position: Q1 2023 in Review

StoneX Group sold out of Corbus Pharmaceuticals (CRBP) in Q1 2023, closing a stake of 437 shares — an estimated $1.45K sold.

StoneX Group first reported a position in CRBP in Q4 2022 and held it in 1 quarter. The position peaked at $1.45K in Q4 2022. 30 funds tracked by Wall St. Rank hold CRBP as of Q1 2023.

StoneX Group reported no remaining Corbus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
StoneX Group sold 437 Corbus Pharmaceuticals shares in Q1 2023, an estimated $1.45K.
StoneX Group first reported a position in Corbus Pharmaceuticals in Q4 2022 and held it in 1 quarter.
StoneX Group's Corbus Pharmaceuticals position peaked at $1.45K in Q4 2022.
30 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.